KYTHERA receives U.S. patent allowance for ATX-101

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."    

"The allowance of this patent application claiming certain forms of synthetic deoxycholic acid adds an additional patent asset to our ATX-101 patent portfolio, a portfolio that already includes patents related to method of use, formulation and manufacturing processes," said Keith Leonard, KYTHERA's President and CEO. "We are pleased to add a compound claim to our intellectual property protection as we continue to investigate the safety and efficacy of ATX-101."

The patent that is issuable from this allowed application, Serial No. 12/541,045, titled "Synthetic Bile Acid Compositions and Methods," is projected to expire in 2028. Once issued, this forthcoming compound patent will be the sixth patent the USPTO has issued in relation to ATX-101. In addition to these U.S. patents, KYTHERA has over 70 issued or allowed patents outside the U.S., including patents in the major markets of Europe covering non-surgical methods of removing localized fat accumulation using deoxycholic acid. KYTHERA also has more than 70 pending worldwide patent applications and is preparing to file additional new patent applications to further strengthen its intellectual property portfolio.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug shows promise for motor neurone disease treatment